Get the Stockscreener App
1.06
0.95%
0.01
After Hours:
1.09
0.03
+2.83%
Tenaya Therapeutics Inc stock is traded at $1.06, with a volume of 1.59M.
It is up +0.95% in the last 24 hours and down -26.90% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
See More
Previous Close:
$1.05
Open:
$1.08
24h Volume:
1.59M
Relative Volume:
0.33
Market Cap:
$86.75M
Revenue:
-
Net Income/Loss:
$-117.23M
P/E Ratio:
-0.7361
EPS:
-1.44
Net Cash Flow:
$-95.25M
1W Performance:
-15.87%
1M Performance:
-26.90%
6M Performance:
-71.51%
1Y Performance:
-75.58%
1-Day Range:
$1.04
$1.12
1-Week Range:
$1.04
$1.28
52-Week Range:
$0.9867
$7.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
1.06 | 86.75M | 0 | -117.23M | -95.25M | -1.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Tenaya Therapeutics announces option repricing to retain staff - Investing.com
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely - Simply Wall St
Tenaya Therapeutics (TNYA) Stock Price, News & Analysis - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Jane Street Group LLC - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33 - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat
HC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya advances gene therapies for heart conditions By Investing.com - Investing.com Canada
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
Tenaya advances gene therapies for heart conditions - Investing.com
Tenaya Therapeutics Advances Gene Therapy Programs with Promising TN-201 Trial Progress - StockTitan
Analysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33 - MarketBeat
Geode Capital Management LLC Increases Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Things To Consider Before Buying Tenaya Therapeutics Inc (NASDAQ: TNYA) - Stocks Register
Zhongzhi drops $3M in Gabaeron series A for stem cell AD therapy - BioWorld Online
Largest borrow rate increases among liquid names - TipRanks
State Street Corp Purchases 9,506 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease (TNYA) - Seeking Alpha
Short Interest in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Grows By 18.8% - MarketBeat
Reviewing Caribou Biosciences (NASDAQ:CRBU) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World
XTX Topco Ltd Has $95,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from Chardan Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World
Tenaya Therapeutics (NASDAQ: TNYA) Senior Vice President Chihiro Saito Resigns: 8-K Filing - Defense World
Tenaya Therapeutics stock backed by H.C. Wainwright on TN-401 safety and protein expression gains - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC Wainwright - MarketBeat
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data - BioSpace
Tenaya Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) & Big Cypress Acquisition (OTCMKTS:BCYP) Critical Comparison - Defense World
Tenaya reports positive early data on heart gene therapy By Investing.com - Investing.com Australia
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Tenaya Therapeutics announces executive departure - Investing.com
Tenaya Therapeutics stock hits 52-week low at $1.49 - Investing.com
Tenaya Therapeutics Reports Promising TN-201 Trial Results - TipRanks
Tenaya Therapeutics’ Senior VP Resigns for New Opportunity - TipRanks
Tenaya reports positive early data on heart gene therapy - Investing.com
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya's Gene Therapy Shows Promise in Early Heart Disease Trial DataKey Clinical Results - StockTitan
Crude Oil Down Over 1%; US Industrial Production Declines In November - Benzinga
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - The Manila Times
Tenaya Therapeutics to Unveil Groundbreaking Gene Therapy Data for Heart Disease Treatment - StockTitan
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Fmr LLC Raises Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – December 11, 2024 - CGTLive™
Tenaya Therapeutics' SWOT analysis: gene therapy stock faces pivotal catalysts - Investing.com
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):